Krystal Biotech Inc (KRYS NASDAQ) stock market data APIs
$141.9923
-1.42(-1%)
as of July 8, 2025
Try our APIs with
free plan!
Krystal Biotech Inc Financial Data Overview
Price chart is built with
Anychart
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Prev. Close
141.9923
Open
140.5737
High
142.3376
Low
138.9979
52 wk Range
122.8-219.34
Market Cap
4 038 M
P/E Ratio
33.5914
Shares Outstanding
28 899 K
Revenue
333 M
EPS
1.1962
Beta
0.661
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Krystal Biotech Inc data using free add-ons & libraries
Get Krystal Biotech Inc Fundamental Data
Krystal Biotech Inc Fundamental data includes:
- Net Revenue: 333 M
- EBITDA: 136 M
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: 1.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Krystal Biotech Inc News
New
Exploring High Growth Tech Stocks In The US Market
Over the last 7 days, the United States market has risen by 1.8%, contributing to a 14% increase over the past 12 months, with earnings forecasted to grow by 15% annually. In this favorable environmen...
High Insider Ownership In 3 Promising Growth Companies
Over the last 7 days, the United States market has risen by 1.8%, and over the past 12 months, it is up by 14%, with earnings forecasted to grow by 15% annually. In this favorable environment, stocks ...
Is Venezuela about to lose Citgo, its most prized foreign asset?
By Marianna Parraga HOUSTON (Reuters) -A U.S. court has received last-minute improved bids in a auction of shares in the parent of Venezuela-owned Citgo Petroleum from at least three consortia, poten...
Krystal Biotech, Inc.'s (NASDAQ:KRYS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
It is hard to get excited after looking at Krystal Biotech's (NASDAQ:KRYS) recent performance, when its stock has declined 23% over the past three months. But if you pay close attention, you might gat...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
